Literature DB >> 6439810

Immunogenicity of homologous low density lipoprotein after methylation, ethylation, acetylation, or carbamylation: generation of antibodies specific for derivatized lysine.

U P Steinbrecher, M Fisher, J L Witztum, L K Curtiss.   

Abstract

We previously showed that immunization of guinea pigs with reductively glucosylated guinea pig low density lipoprotein (LDL) or albumin resulted in the formation of antibodies specific for the glucosylated protein. The present studies were done to determine if modifications of homologous LDL or albumin, other than addition of carbohydrate, would also render these proteins immunogenic. We found that derivatization of lysine residues of guinea pig LDL or albumin by carbamylation, acetylation, ethylation, or even methylation rendered them immunogenic in guinea pigs. In addition, the specificity of the antibodies was strikingly influenced by whether modified homologous LDL or modified homologous albumin was used as the immunogen. Antibodies generated against modified LDL were directed almost exclusively against the derivatized lysine residues (i.e., carbamyllysine, acetyllysine, or methyllysine) and hence reacted equivalently with other modified proteins that contained the same lysine derivative. However, antibodies generated against guinea pig albumin (or fibrinogen) modified in the same ways reacted primarily with the modified protein used as immunogen, and not with the free lysine derivative, or with other similarly modified proteins. Each of the modifications referred to above could potentially occur in vivo. Therefore, the findings presented may be relevant to autoantibody formation and immunopathogenetic mechanisms in certain diseases.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6439810

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  37 in total

1.  Patients with systemic vasculitis have increased levels of autoantibodies against oxidized LDL.

Authors:  B P Swets; D A Brouwer; J W Tervaert
Journal:  Clin Exp Immunol       Date:  2001-04       Impact factor: 4.330

2.  Reduction of oxidative stress and modulation of autoantibodies against modified low-density lipoprotein after rosuvastatin therapy.

Authors:  Ulrike Resch; Franz Tatzber; Alexandra Budinsky; Helmut Sinzinger
Journal:  Br J Clin Pharmacol       Date:  2006-03       Impact factor: 4.335

3.  Distribution of IgM and IgG antibodies to oxidized LDL in immune complexes isolated from patients with type 1 diabetes and its relationship with nephropathy.

Authors:  Gabriel Virella; Rickey E Carter; Antonio Saad; Edward G Crosswell; B Andrew Game; Maria F Lopes-Virella
Journal:  Clin Immunol       Date:  2008-06       Impact factor: 3.969

Review 4.  Atherogenesis and the humoral immune response to modified lipoproteins.

Authors:  Gabriel Virella; Maria F Lopes-Virella
Journal:  Atherosclerosis       Date:  2008-04-12       Impact factor: 5.162

Review 5.  Degradative covalent reactions important to protein stability.

Authors:  D B Volkin; H Mach; C R Middaugh
Journal:  Mol Biotechnol       Date:  1997-10       Impact factor: 2.695

6.  Antiphospholipid antibodies are directed against epitopes of oxidized phospholipids. Recognition of cardiolipin by monoclonal antibodies to epitopes of oxidized low density lipoprotein.

Authors:  S Hörkkö; E Miller; E Dudl; P Reaven; L K Curtiss; N J Zvaifler; R Terkeltaub; S S Pierangeli; D W Branch; W Palinski; J L Witztum
Journal:  J Clin Invest       Date:  1996-08-01       Impact factor: 14.808

Review 7.  Beyond citrullination: other post-translational protein modifications in rheumatoid arthritis.

Authors:  Leendert A Trouw; Theo Rispens; Rene E M Toes
Journal:  Nat Rev Rheumatol       Date:  2017-03-09       Impact factor: 20.543

8.  Increased immunogenicity of some native antigenic determinants in a chemically changed human albumin.

Authors:  L Fiume; C Busi; A Mattioli; G Spinosa
Journal:  Naturwissenschaften       Date:  1987-12

9.  Inhibition of T cell response to native low-density lipoprotein reduces atherosclerosis.

Authors:  Andreas Hermansson; Daniel F J Ketelhuth; Daniela Strodthoff; Marion Wurm; Emil M Hansson; Antonino Nicoletti; Gabrielle Paulsson-Berne; Göran K Hansson
Journal:  J Exp Med       Date:  2010-05-03       Impact factor: 14.307

Review 10.  Why are low-density lipoproteins atherogenic?

Authors:  S G Young; S Parthasarathy
Journal:  West J Med       Date:  1994-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.